Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2014-04-17 Regulatory Filings
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
NeuroVive presents medical breakthrough in cellular energy regulation
Regulatory Filings Classification · 1% confidence The document is explicitly titled and formatted as a "NEWS RELEASE" from NeuroVive Pharmaceutical AB, dated April 17, 2014. It announces a scientific breakthrough, provides updates on drug development pipelines (CicloMulsion®, NeuroSTAT®), and mentions the publication of patent applications. This format—a brief, timely announcement of significant corporate or scientific developments, often released to the public via news wires—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a comprehensive financial report (like 10-K or IR), nor a transcript (CT), nor a specific management discussion (MDA), and it is announcing results/developments rather than just announcing the publication of a report (RPA), the most fitting category for a press release detailing operational and scientific progress is Earnings Release (ER), as these often contain operational highlights alongside financial context (though financial details are sparse here, the structure aligns with an ER/operational update press release). Given the focus on scientific progress and pipeline updates rather than quarterly financial figures, it could also be RNS, but ER is often used for major operational announcements like this one detailing a 'breakthrough'. Since it is a formal announcement of key operational/scientific news, ER is the primary fit, with RNS as a secondary possibility if ER is strictly reserved for financial results only. Given the context of a 'NEWS RELEASE' announcing major developments, ER is chosen.
2014-04-17 English
NeuroVives aktie handlas nu även på OTC-marknaden i USA
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESSMEDDELANDE" (Press Release) and is dated April 10, 2014. The content announces a specific corporate action: the company's stock is now trading on the OTC market in the USA under the ticker NEVPF:US. This is a general, time-sensitive announcement regarding market activity, not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a formal regulatory filing like a proxy statement. Since it is a general corporate announcement that doesn't fit the highly specific categories like DIRS, DIV, or CAP, the most appropriate classification is the general regulatory announcement/miscellaneous category, RNS (Regulatory Filings), as per the fallback rule, although it functions very much like a press release announcing market access.
2014-04-10 Swedish
NeuroVive Stock Now Trading in the USA on the OTC Market
Regulatory Filings Classification · 1% confidence The document is a 'NEWS RELEASE' dated April 10, 2014, announcing that NeuroVive Stock is now trading on the OTC Market in the USA under the ticker NEVPF:US. This announcement details a change in the company's trading venue and market access for US investors, which relates to its capital structure and investor relations activities. It is not a full financial report (10-K, IR), an earnings release (ER), a dividend notice (DIV), or a management change (MANG). It is a specific announcement concerning the company's stock listing and trading mechanism. This type of announcement, which details changes related to the company's securities trading outside of standard mandatory financial filings, fits best under 'Capital/Financing Update' (CAP) as it directly impacts how capital is raised/traded, or potentially 'Regulatory Filings' (RNS) as a general announcement. Given the focus on the stock trading mechanism and market access extension, CAP is a strong fit, but since it is a general news release about market access rather than a formal financing round or share issue, RNS (Regulatory Filings/General Announcement) is often used for such market-related news that doesn't fit a more specific category like SHA or POS. However, since it directly relates to the accessibility and trading of its shares in a new market, it is fundamentally a capital/financing-related event for investor access. I will classify it as CAP as it pertains to the structure of how the company's shares are traded and accessed by investors, which is a financing mechanism.
2014-04-10 English
Invitation to the AGM of NeuroVive Pharmaceutical AB (publ)
AGM Information Classification · 1% confidence The document is explicitly titled "Invitation to the AGM of NeuroVive Pharmaceutical AB (publ)" and details the date, time, location, registration procedures, proposed agenda items (including election of Chairman, approval of accounts, election of Board members, and remuneration guidelines), and specific proposals for shareholder voting. This content is characteristic of materials distributed to shareholders in advance of an Annual General Meeting (AGM). Therefore, the correct classification is AGM Information (AGM-R).
2014-04-09 English
Kallelse till årsstämma i NeuroVive Pharmaceutical AB (publ)
AGM Information Classification · 1% confidence The document is titled "Kallelse till årsstämma i NeuroVive Pharmaceutical AB (publ)" which translates to "Notice of Annual General Meeting in NeuroVive Pharmaceutical AB (publ)". It details the date, time, location, registration procedures, agenda items (including election of chairman, approval of financial statements, remuneration guidelines, and authorization for new share issues), and specific proposals to be voted upon at the meeting. This content is characteristic of a formal notice and agenda for an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2014-04-09 Swedish
Major Shareholding Notification 2014
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding percentage for a specific holder (Maas Biolab, LLC) in the issuer (Abliva AB). It explicitly states the 'Reason for major shareholding notification Sell' and provides 'Before the transaction' and 'After the transaction' figures, culminating in a new percentage (13.9499%). This structure perfectly matches the definition of a Major Shareholding Notification, which is classified as 'MRQ'. The document is short and contains the final data, not an announcement about a report.
2014-04-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.